Table 2. Results of Laboratory Testing in 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
| Deficiency group (n = 160) | Detectable group (n = 54) | P Value | |
| Hemoglobin level, g/dL | 8.1 (2.2) | 8.7 (2.1) | .06 |
| Reticulocyte count, ×109/L | 185 (118) | 106 (80.1) | <.0001 |
| LDH level, U/L | 6.0 (4.6) | 5.8 (3.5) | .70 |
| Platelet count, ×109/L | 17.4 (14.2) | 66.6 (49.3) | <.0001 |
| Creatinine level, µmol/L mg/dL | 114 (68.4) 1.29 (0.77) | 454 (326) 5.13 (3.68) | <.0001 |
| Estimated GFR, mL/min | 80.6 (33.3) | 35.0 (59.2) | <.0001 |
| ANA | 85 (53%)1 | 13 (24%)2 | <.001 |
| Anti-dsDNA antibodies | 9 (7%)3 | 0 (0%)4 | .21 |
| Anticardiolipin antibodies | 14 (11%)3 | 9 (20%)5 | .11 |
Data are presented as mean (standard deviation) or number (percent).
1
21 patients had anti-extractable nuclear antigen antibodies, including anti-SSA antibodies in 12 cases, anti-SSA antibodies associated with anti-SSB antibodies in 5 cases, and anti-U1-snRNP antibodies in 4 cases.
2
1 patient had anti-SSA antibodies.
The analysis was performed on 1273, 354 and 455 patients.
Abbreviations: ANA, antinuclear antibodies; Anti-dsDNA, anti-double-stranded DNA; GFR, glomerular filtration rate.